The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 02, 2023
Filed:
Sep. 29, 2020
Applicant:
Horizon Therapeutics Usa, Inc., Deerfield, IL (US);
Inventors:
Theresa Rosario-Jansen, Randolph, NJ (US);
David Erick Wright, Ramona, CA (US);
Assignee:
Horizon Therapeutics USA, Inc., Deerfield, IL (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/62 (2006.01); G01N 33/53 (2006.01); G01N 33/68 (2006.01); C12N 9/02 (2006.01); A61K 47/60 (2017.01); A61P 19/02 (2006.01); A61K 9/00 (2006.01); A61K 38/44 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5308 (2013.01); A61K 9/0019 (2013.01); A61K 38/44 (2013.01); A61K 47/60 (2017.08); A61P 19/02 (2018.01); C12Y 107/03003 (2013.01); G01N 33/6893 (2013.01); G01N 2333/90694 (2013.01); G01N 2800/107 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01);
Abstract
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.